HIV Eradication Hinges on System Redesign, Not New Drugs

Achieving the end of the HIV epidemic hinges on a comprehensive redesign of healthcare and social systems, rather than solely on the discovery of new pharmaceutical interventions. This perspective challenges the traditional approach of seeking novel drugs or treatments as the primary solution.

The existing toolkit, which includes antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and rapid diagnostics, has been available for decades. Coupled with extensive implementation science, these tools have demonstrated significant potential. However, their full impact is being hampered by systemic inefficiencies and barriers.

These systemic issues encompass a range of factors, including access to care, stigma, socioeconomic determinants of health, and the fragmentation of services. Addressing these deeply ingrained problems requires a multi-faceted strategy that goes beyond biomedical advancements. It necessitates improved public health infrastructure, enhanced community engagement, and policy changes that promote equity and reduce barriers to prevention and treatment.

Therefore, the focus must shift from a purely biomedical model to a more holistic, systems-level approach. This involves strengthening existing programs, ensuring equitable distribution of resources, and actively working to dismantle the social and structural factors that perpetuate the epidemic. The consensus among many public health experts is that a fundamental overhaul of how HIV prevention, treatment, and support are delivered is the critical path forward to achieving an end to the epidemic.